Group 1 - MiNK Therapeutics, Inc. (INKT) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook for the stock due to rising earnings estimates [1][4][9] - The Zacks rating system is beneficial for investors as it reflects changes in earnings estimates, which are crucial for stock price movements [2][5] - The upgrade positions MiNK Therapeutics in the top 5% of Zacks-covered stocks, suggesting potential for near-term stock price increases [7][14] Group 2 - Over the past three months, the Zacks Consensus Estimate for MiNK Therapeutics has increased by 29.7%, indicating a significant upward revision in earnings expectations [12] - The company is projected to earn -$0.42 per share for the fiscal year ending December 2024, reflecting a year-over-year change of 35.4% [13] - The Zacks Rank system has a strong track record, with Zacks Rank 1 stocks generating an average annual return of +25% since 1988, highlighting the potential for market-beating returns [11]

Core Viewpoint - MiNK Therapeutics, Inc. is set to hold its Annual Shareholders Meeting virtually on June 12, 2024, focusing on its innovative iNKT cell therapies for cancer and immune-mediated diseases [1][4]. Group 1: Meeting Details - The Annual Shareholders Meeting will commence at 9:30 a.m. ET on June 12, 2024, with registration starting at 9:15 a.m. ET [1]. - Shareholders can participate by visiting a specific website and entering a control number, while guests can listen without a control number [2]. - A live webcast and replay of the meeting will be available on the company's website [3]. Group 2: Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on the development of allogeneic invariant natural killer T (iNKT) cell therapies [4]. - The company is advancing a pipeline of both native and engineered iNKT programs, emphasizing scalable and reproducible manufacturing for off-the-shelf delivery [4]. - MiNK Therapeutics is headquartered in New York, NY, and provides regular updates for investors through its website and social media [4].

Core Insights - MiNK Therapeutics, Inc. announced clinical data on agenT-797 for treating severe acute respiratory distress syndrome (ARDS) at the American Thoracic Society Annual Meeting, highlighting its potential in addressing critical unmet needs in immune-compromised patients [1][2]. Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, with a scalable manufacturing platform for off-the-shelf delivery [5]. Clinical Findings - A 26-year-old patient with chronic immunosuppression post-renal transplant contracted COVID-19 and developed severe hypoxemic respiratory failure, treated with a single dose of 1x10^9 allogeneic iNKT cells (agenT-797) [8]. - Following treatment, there was a rapid decrease in inflammatory cytokines, and the patient was extubated on day 37, discharged on day 60, and returned to normal activities within 6 months [8].

EXHIBIT 99.1 MiNK Reports First Quarter 2024 Results NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune- mediated diseases, today announced results for the first quarter 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET to discuss the r ...

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical- stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the first quarter 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. "This quarter w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2142067 (St ...

Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board Observer NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediat ...

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 14, 2024. MiNK executives will host a conference call and webcast ...

MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid modelsMiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activation NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today ann ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40908 MiNK Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Securities registered pursuant to Section 12(b) ...